ANRO — Alto Neuroscience, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1999480 ·
Last close
$36.25
Market Cap
$1.42B
52W High
$36.99
52W Low
$17.90
ADV30
468,634
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,138,000 | -26,237,000 | 276,259,000 | 263,762,000 | 32,890,000 |
| Dec 2025 | 0 | — | -17,055,000 | -16,182,000 | 184,689,000 | 176,484,000 | 33,547,000 |
| Sep 2025 | 0 | — | -14,951,000 | -14,181,000 | 147,006,000 | 137,816,000 | 35,449,000 |
| Jun 2025 | 0 | — | -18,682,000 | -17,706,000 | 157,877,000 | 147,585,000 | 34,465,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,304,000
Investing CF
$-556,000
Financing CF
$165,892,000
CapEx
$-1,086,000
Dividends Paid
—
Buybacks
$-4,875,000
EPS Diluted TTM
$-2.53
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,871,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-71,890,000
Pretax Income TTM
$-74,306,000
Interest Exp TTM
$2,416,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,364,000 | -63,238,000 | 184,689,000 | 33,547,000 | — | -51,769,000 |
| Dec 2024 | 0 | -68,610,000 | -61,431,000 | 177,542,000 | 26,082,000 | — | -47,424,000 |
| Dec 2023 | 0 | -37,809,000 | -36,305,000 | 86,628,000 | 158,300,000 | — | -33,448,000 |
| Dec 2022 | 0 | -27,455,000 | -27,710,000 | 50,854,000 | 89,260,000 | — | -20,394,000 |
TTM Snapshot
Revenues TTM
$3,214,000
NetIncome TTM
$-25,924,000
OpCashFlow TTM
$0
Assets (Latest)
$177,542,000
Forward EPS
$-3.29
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $36.25 · call volume: 1 · put volume: 300Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OMER | OMEROS CORP | $1.40B | $19.32 | — |
| AKTS | Aktis Oncology, Inc. | $1.40B | $25.98 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.40B | $13.46 | — |
| AVBP | ArriVent BioPharma, Inc. | $1.39B | $28.26 | — |
| JBIO | Jade Biosciences, Inc. | $1.36B | $21.33 | — |
News headlines (Yahoo Finance, 1h cache)
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
2026-08-16 20:07 · Yahoo
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
2026-08-16 08:08 · Yahoo
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
2026-08-16 03:16 · Yahoo
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
2026-07-13 11:47 · Yahoo
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
2026-07-02 19:58 · Yahoo
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
2026-06-15 12:03 · Yahoo
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
2026-04-02 18:36 · Yahoo
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
2026-04-02 20:10 · Yahoo
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
2026-04-02 12:20 · Yahoo
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 20:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.